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meetings to review circumstances surrounding falls.
Medications review to determine those that most greatly
increase risk of falls. Patients not assessed as high fall risk
were placed on bed alarms for two hours after receiving
these meds.
All staff members received education on Crucial Conver-
sations and how to address patients’ refusal of bed alarm
usage.
Continued refusal of the bed alarm was escalated to
nursing leadership.
Collaboration with Physical Therapyethe use of a
communication board to report activity and required assis-
tance by staff.
Findings & Interpretation: 2012 total falls were 19, fall rate
3.02/ 1000 patient days.
2013 total falls were 27, fall rate 4.45/ 1000 patient days.
2014 falls through 3rd quarter is 10, fall rate 2.08/ 1000
patient days.
Discussion & Implications: Consistent implementation of
any strategy is the best way to ensure sustained results.
Nurse leader rounding to validate use of the bed alarm and
consistent messaging to staff and patients is necessary to
keep protocols high priority.
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Topic Signiﬁcance & Study Purpose/Background/Rationale:
Autologous stem cell transplant (ASCT) and various novel
drug combination strategies are designed to improve
outcome. Relapse within 12 months of stem cell transplant
predicts poor outcome for patients with (MM). Historically,
extramedullary plasmacytomas are not included in staging or
as a prognostic feature for patients undergoing transplants for
multiple myeloma.
Methods, Intervention, & Analysis: We evaluated charac-
teristics of plasmacytomas (PCM) in patients undergoing
ASCT transplant for diagnosis of MM. We retrospectively
analyzed 251 consecutive (M137:F107) ASCTs for MM be-
tween December 2011 and June 2014, after new triple com-
bination agents were introduced in the therapy of (MM).
Median agewas 57 years (38-76) and length of follow-upwas
538 days (120 - 1042 days). Bone marrow cytogenetics was
available in 230 (94.3%) patients. Various pretransplantcharacteristics including age, cytogenetics, and plasma cell
percentage were evaluated for impact on overall survival and
disease progression.
A total of 159 (65%) patients had either extraosseous or
extramedullary plasmacytomas at presentation and 85 (35%)
patients had no lytic lesions or any plamacytomas. 52 (21.3%)
patients had extramedullary PCM without any lytic lesions.
Plasma cells > 20% was seen in 38.2% (n¼20) in PCM
compared to 62% (n¼152) in whole group. Prior MGUS
(n¼26) or smoldering myeloma (n¼7) was seen in 14% (33/
244) patients but only 7.6% (4/52) in PCM group. Prior soli-
tary Plasmacytomas were seen in 21%( 11/52) PCM patients.
Trisomy 11 or t (11:14) was seen in 3% (n¼8) in PCM
compared to 12% (n¼6) in all pts. Hyperdiploidy was seen in
4% (2/52) compared to 9% (22/244) patients.
Findings & Interpretation: The median survival was 623
days (20 days -1897 days) for PCM patients compared to 522
days (89 days -1897 days) for all patients. PCM pts developed
recurrent PCM after autologous transplant in 33% (17/52)
cases. One third of patients with recurrent PCM (6/17) died of
(PCM) progression.
Discussion & Implications: In conclusion, patients pre-
senting as PCM have more aggressive clinical presentation.
Pre and post transplant strategies need to be better deﬁned
to improve outcome of patients with PCM recurrences post
transplant.586
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Topic Signiﬁcance & Study Purpose/Background/Rationale:
Prolonged neutropenia and mucosal barrier breakdown are
major treatment related toxicities contributing to central line
associated blood stream infections (CLABSIs) in bone marrow
transplant recipients. CLABSIs are preventable, costly, and
potentially deadly. Bone Marrow Transplant nurses have the
ability to reduce the number of CLABSIs through a variety of
techniques and practices.
Methods, Intervention, & Analysis: An evaluation of cur-
rent practice and areas for improvement were identiﬁed
which led to the development of a comprehensive unit based
safety program (CUSP) team. A “Back to Basics Campaign”
was initiated by the team that included proper hand hygiene,
aseptic techniques when accessing central lines, environ-
mental practices, and blood culture procedure techniques.
Additionally, there were speciﬁc nurse and patient educa-
tion, environmental practices (i.e., high-touch surface infec-
tion control, decreasing clutter in recipient rooms, ultra
violet light decontamination cleaning, isolation practice
changes), and CLABSI drill downs by the clinical nurse leader
and team. CLABSI rates were measured before and after
implementation of education and clinical practice changes.
The overall goals were to improve patient outcomes and
reduce CLABSI rates below national benchmark. Compliance
audits were performed weekly by nursing leadership to
validate nurse and patient practices.
Findings & Interpretation: CLABSI rates prior to imple-
mentation were 9.938 and three months after the in-
terventions were 2.42. Mucosal barrier infections were
unpreventable and included in the data.
